Latest Posts

30

May 24

Partex and Singapore’s Experimental Drug Development Centre collaborate to bring forward an innovative approach for early drug discovery and development

Frankfurt, Germany, 3rd June 2024, 9am CET Partex, a leading provider of AI-driven solutions in the pharmaceutical industry, is thrilled...
Read More

22

Apr 24

Partex Partners with Lupin to Revolutionize Drug Discovery through AI-Driven Asset Search and Evaluation

Frankfurt, Germany, 23 April 2024 – Partex, a leading provider of AI-driven solutions in the pharmaceutical industry, is thrilled to...
Read More

Innoplexus wins Horizon Interactive Gold Award for Curia App

Read More
Try Ontosight® For Free

Category: Press release 2022

Innoplexus-Innovatrix-partnership

Innoplexus and Innovatrix capital partner to bring about new risk-transfer solutions for the life science industry

Artificial Intelligence (AI) pioneer Innoplexus and London based Parametric Insurance start-up, Innovatrix Capital, collaborating upon using AI & Machine Learning (ML) to bring about new risk-transfer solutions for the life science industry. Eschborn, Germany/London, U.K., 27 July 2022Innoplexus AG is pleased to announce that an agreement for a strategic partnership with Innovatrix Capital Ltd. has …

Innoplexus and Innovatrix capital partner to bring about new risk-transfer solutions for the life science industry Read More »

Innoplexus and Inflection Biosciences enter strategic collaboration based on Artificial Intelligence

Innoplexus and Inflection Biosciences enter strategic collaboration based on Artificial Intelligence to expedite PIM kinase inhibitor development ESCHBORN, Germany, May 30, 2022 – Innoplexus, a global leader in AI-based drug discovery and development, and Inflection Biosciences Ltd., an innovative biotechnology company focused upon developing innovative small molecule therapeutics for the treatment of cancer, autoimmune and …

Innoplexus and Inflection Biosciences enter strategic collaboration based on Artificial Intelligence Read More »